The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination

@inproceedings{SkelhorneGross2012TheKT,
  title={The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination},
  author={Graham EA Skelhorne-Gross and C. J. Nicol},
  booktitle={PPAR research},
  year={2012}
}
Despite extensive preclinical evidence that peroxisome proliferator-activated receptor (PPAR)γ activation protects against tumourigenesis, results from a few clinical trials using PPARγ ligands as monotherapy show modest success. In spite of this, several groups reported exciting results with therapeutic regimens that combine PPARγ ligands with other compounds: chemotherapeutic agents, retinoid x receptor (RXR)α agonists, statins, or cell-to-cell signaling molecules in preclinical cancer models… CONTINUE READING

From This Paper

Topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 117 references

Cancer Fact Sheet #297

  • World Health Organization
  • 2012, http://www.who.int/mediacentre/factsheets…
  • 2012

American cancer statistics

  • American Cancer Society
  • 2011, http://www.cancer.org/Cancer/BreastCancer…
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…